SLC22A6 and urogenital neoplasm: Immunostaining of kidney sections showed more abundant expression of the renal injury marker kidney injury molecule‐1 (KIM1) and myofibroblast marker alpha‐smooth muscle actin (a‐SMA), and less abundant expression of renal tubule markers ATPase Na+/K+ transporting subunit alpha 1 (ATP1A1) and solute carrier family 22 member 6 (SLC22A6) in the cisplatin‐injured kidneys, and only R.C. EPO treatment could alleviate the level of kidney damage (Figures 2G and S1A).